Patent Yard Sign in
Canadian application, no grantCanada

Nucleotide sequences encoding variable regions of heavy and light chainsof monoclonal antibody 1f7

CA 2434209 A1 · Owner: Muller, Sybille · Inventors: Muller, Sybille; Kohler, Heinz

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

Nucleotide sequences encoding the variable heavy and light chains of the murine monoclonal antibody 1F7 are disclosed. The 1F7 antibody is an effective immune modulator that has anti-idiotypic binding affinity for anti-HIV antibodies. Polypeptides containing at least one complementarity-determining region (CDR) or framework-determining region (FR) of the variable heavy or variable light chains of 1F7, as well as the polynucleotides encoding them can be used to modulate the immune response to HIV infection. Unnecessary and , potentially adverse, murine segments of the variable chains falling outside the CDRs can be replaced with human sequences to afford humanized chimeric antibodies …

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed January 11, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 11, 2022.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 11, 2024.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledJanuary 11, 2002
GrantedNo grant recorded
Term endedJanuary 11, 2022
Patent numberCA 2434209 A1
Classification (IPC)C12N15/13 +2 more

Timeline

Timeline From CIPO dates

2003200520072009201120132015201720192021Application filedJan 11, 2002Term endedJan 11, 2022

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.